about
Cancer immunoediting from immune surveillance to immune escapeTGF-β signaling and its targeting for glioma treatmentPosttranscriptional regulation of cancer traits by HuRNon-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interactionTGF-β signaling in T cells: roles in lymphoid and epithelial neoplasiaBone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor statusTransforming growth factor-β1 and -β2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitroModulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy.Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy.HuR function in disease.Review article: immune suppression and colorectal cancer.Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patientsImmunology and immunotherapy approaches for prostate cancer.Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinomaThe adaptive immune response to sporadic cancer.Role of the extracellular matrix in variations of invasive pathways in lung cancers.Exploring anti-TGF-β therapies in cancer and fibrosis.Immune system: a double-edged sword in cancer.Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell PlasticityManipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.Tumor cell secretion of soluble factor(s) for specific immunosuppression.Immunoregulation through IL-10 gene expression and the fate of cytotoxic T lymphocyte-mediated tumor immunotherapy.Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy.Immune checkpoint inhibitors in renal cell carcinoma.Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages.Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses.Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.Ki-67, TGF-β1, and elastin content are significantly altered in lip carcinogenesis.Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma.Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
P2860
Q24655415-6516DAFC-D3F5-4F4A-B9D6-05AF5AADA520Q28082042-18431F82-4617-4843-8C03-96CC68CA2627Q28248667-09309069-D45D-4A7E-997E-9B27C527DD3AQ28363575-7E31BB4A-A42B-4D20-8F49-416EA7524288Q28972215-6E8A28DE-5941-400D-98AF-32D844AA5DBDQ29036999-6E8F0847-10BD-4E8F-9EA8-31838F4EC6A9Q33702352-7E982509-2D27-4DF7-A74B-C5B8EC784D23Q34559243-D2A4AADB-F6E6-4851-A31E-B3B4BFC25CBDQ34791108-7EB5B028-3ABC-4739-9F65-AC96695C09A2Q35093612-C8B47B82-976A-4581-ADD0-6B742673CC7DQ35583991-B2AF40A4-F27C-4984-A682-8EE137651F66Q35966719-32147768-42A0-4285-A1B5-89610E71A230Q36609898-65454D06-27A1-4779-8819-1E4150DDE438Q36610882-BF930563-4E25-4312-87C4-46E90744ADE2Q36786512-C6872BBD-1DA0-424C-8698-9164C3C10D23Q36849038-9D6EA0F3-74C9-4842-94A9-592DF5123512Q36990593-9EDF51BD-52A2-42E2-8604-7D8CB4D00EDAQ37371321-C95E127D-F82B-4BCA-8836-ACDD389A2FD8Q37896073-0EF634EE-E3DB-4EC4-AEE6-E9B45E6D2254Q38122647-98C52239-A4F4-4401-9EA1-82536ABF3AE0Q38196804-C5FCBC23-9E6B-4A78-A03E-E079F6632310Q38253084-E8301CEA-A9FF-4791-9392-A78D03FDB45BQ38902833-C7A876DD-AFE6-4BD2-9333-3C9597AE657AQ39825964-0E0C6BD0-8F2C-4FB4-8627-B711658CB321Q40277998-F0A8AA81-E5D8-4941-8F89-00BF0225EF8AQ40498268-156930FA-3B02-43D5-A084-81BFBB172F01Q47592718-1CFE6D19-DADB-48F9-9C08-56B98DEC0399Q51615623-88AF6B4F-F94F-4E25-AB53-BC96E2DEF595Q52599425-350B220E-22B9-4C4A-A122-179DA4B80B7DQ52936850-A9367F82-9212-4E01-9B30-6C29DA32A4B4Q53238186-FE0D72E4-3E2F-4B21-BFE8-0395D07722E6Q54357735-A4A01252-5DF0-47F6-A6E8-42CAEF0C57F2Q57142667-C465A0A2-BE22-4B8C-A6AA-E337C09815B5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Role of TGF-beta in immune-evasion of cancer.
@ast
Role of TGF-beta in immune-evasion of cancer.
@en
Role of TGF-beta in immune-evasion of cancer.
@nl
type
label
Role of TGF-beta in immune-evasion of cancer.
@ast
Role of TGF-beta in immune-evasion of cancer.
@en
Role of TGF-beta in immune-evasion of cancer.
@nl
prefLabel
Role of TGF-beta in immune-evasion of cancer.
@ast
Role of TGF-beta in immune-evasion of cancer.
@en
Role of TGF-beta in immune-evasion of cancer.
@nl
P2093
P2860
P1476
Role of TGF-beta in immune-evasion of cancer.
@en
P2093
P2860
P304
P356
10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W
P577
2001-02-01T00:00:00Z